Loading
Drug candidates are tested for shrinking tumours, almost never for stopping spread. A standard spread test would find anti-metastatic drugs we are throwing away.
Barcoded in vivo CRISPR and lineage-tracing screens can quantify seeding, survival in circulation and outgrowth as separate phenotypes. Very few programmes run them, so anti-metastatic activity is invisible during discovery. Funders could require a standard metastasis panel (spontaneous metastasis from orthotopic implantation plus a barcoded seeding assay) from any grant or programme claiming anti-metastatic intent.
Shares Cancer Models (PDCM Finder) & HCMI, Patient-derived xenografts, Patient-derived organoids, Lab models that fail to predict what happens in patients.
Shares Cancer Models (PDCM Finder) & HCMI, DepMap (Cancer Dependency Map), Patient-derived xenografts, Patient-derived organoids.
Shares Patient-derived xenografts, CRISPR functional genomics, Patient-derived organoids, Lab models that fail to predict what happens in patients.
Shares Are 90% of deaths from cancer caused by metastases?, Patient-derived xenografts, Metastasis is understood least and studied last, Patient-derived organoids.
Shares Patient-derived xenografts, Metastasis is understood least and studied last, Patient-derived organoids, Lab models that fail to predict what happens in patients.
Shares DepMap (Cancer Dependency Map), CRISPR functional genomics, Patient-derived organoids, Lab models that fail to predict what happens in patients.
Shares Cancer Models (PDCM Finder) & HCMI, Patient-derived xenografts, Patient-derived organoids, Lab models that fail to predict what happens in patients.
Shares Cancer Models (PDCM Finder) & HCMI, DepMap (Cancer Dependency Map), Patient-derived organoids, Lab models that fail to predict what happens in patients.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/